



Express Mail No. EV473971020US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dingivan, Christine A. Confirmation No.: 7146
Serial No.: 10/091,313 Art Unit: 1644
Filed: March 4, 2002 Examiner: Skelding, Zachary
For: METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING CD2 BINDING MOLECULES IN COMBINATION WITH ANTI-ANGIOGENIC AGENTS (as amended) Attorney Docket No.: 10271-063-999

FEE TRANSMITTAL SHEET

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.00.

The claim amendment fee has been estimated as shown below:

(Col. 1)			(Col. 2)		(Col. 3)		<input type="checkbox"/> SMALL ENTITY		<input checked="" type="checkbox"/> OTHER THAN A SMALL ENTITY														
CLAIMS REMAINING AFTER AMENDMENT			HIGHEST NO. PREVIOUSLY PAID		PRESENT EXTRA		RATE		ADDIT. FEE		OR		RATE		ADDIT. FEE								
TOTAL			36		MINUS		182		0		x 25		\$		x 50		\$		0.00				
INDEP.			2		MINUS		12		0		x 100		\$		x 200		\$		0.00				
<input type="checkbox"/>			FIRST PRESENTATION OF MULTIPLE DEP. CLAIM															\$		\$		0.00	
									TOTAL			\$		OR			TOTAL			\$		0.00	

Please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Respectfully submitted,

Date: March 12, 2007

By:

Anthony M. Insogna 35,203
Anthony M. Insogna (Reg. No.)
Jennifer J. Chheda 46,617
Jennifer J. Chheda (Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosure



Express Mail No.: EV473971020US
Attorney Docket No.: 10271-063-999
Application Serial No.: 10/091,313

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Dingivan, Christine A.	Confirmation No.:	7146
Serial No.:	10/091,313	Art Unit:	1644
Filed:	March 4, 2002	Examiner:	Skelding, Zachary
For:	METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING CD2 BINDING MOLECULES IN COMBINATION WITH ANTI- ANGIOGENIC AGENTS (as amended)		
		Attorney Docket No.:	10271-063-999

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed October 11, 2006, and in accordance with Rule 111 of the Rules of Practice, Applicant respectfully requests that the Examiner consider and enter into the record of the present application the remarks and amendments below. Applicant submits herewith: (1) a Petition for Extension of Time with a provision authorizing payment of the required fee; (2) an Amendment Fee Transmittal with a provision authorizing payment of the required fee; (3) a Supplemental Information Disclosure Statement with a provision authorizing payment of the required fee; and (4) a revised PTO-1449 Form along with copies of references B24 to C152-C158 listed on the revised PTO-1449 Form.

It is believed that no additional fees are due in connection with the filing of this Response. However, in the event that an additional fee is required, the Commissioner is hereby authorized to charge the required fee(s) to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed for such purpose.

Amendments to the Specification begin on page 2.

Amendments to the Claims begin on page 11.

Remarks begin on page 15.

Amendment